As of Nov 19, 2026, 1 of 2 active firms rate IRWD a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IRWD EPS & revenue forecast
EPS · NEXT QUARTER
$0.30
Range $0.26 – $0.35 · 2 analysts · +27% YoY
Next period, 2 analysts expect Ironwood Pharmaceuticals Inc to earn $0.30 a share (range $0.26 – $0.35), versus $0.24 a year earlier. Full-year consensus is $1.30, growing to $1.57 the year after.
REVENUE · NEXT QUARTER
$108.9M
Range $108.9M – $108.9M · 2 analysts · +2% YoY
Revenue is expected to reach $108.9M (range $108.9M – $108.9M), +2.2% year-over-year. Full-year consensus is $493.6M, rising to $504.2M next year.
Top analysts covering Ironwood Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IRWD.
#1
Chase Knickerbocker
Craig-Hallum · Rank #17
Buy
No targeton IRWD
Overall win rate
61%
+ Follow
#2
Jason Butler
JMP Securities · Rank #62
Buy
$10.00+108.8% to target
Overall win rate
49%
+ Follow
#3
Roy Buchanan
JMP Securities · Rank #176
Buy
$14.00+192.3% to target
Overall win rate
47%
+ Follow
#4
Mohit Bansal
Wells Fargo
Neutral
$5.00+4.4% to target
Coverage
—
+ Follow
#5
JN
Jason N. Butler
Citizens
Buy
$10.00+108.8% to target
Coverage
—
+ Follow
IRWD stock forecast FAQ
What is IRWD's average 12-month price target?+
The 2 active firms with a live target average $7.50 for Ironwood Pharmaceuticals Inc over the next 12 months, ranging from a $10.00 high to a $5.00 low, as of Nov 19, 2026.
Is IRWD stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IRWD?+
The Street-high target is $10.00 (Citizens), and the Street-low is $5.00 (Wells Fargo). The average of all 2 active-firm targets is $7.50.
How many active Wall Street firms cover IRWD?+
2 active firms have a recognized rating on Ironwood Pharmaceuticals Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IRWD?+
Among analysts who currently cover IRWD, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #17). Their current call is Buy.
What is Ironwood Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.30 per share (range $0.26 – $0.35) across 2 analysts. Full-year EPS is projected at $1.30, rising to $1.57 the following year.
How much revenue is Ironwood Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $108.9M (range $108.9M – $108.9M). Full-year revenue is projected at $493.6M, growing to $504.2M next year.
Have analysts been upgrading or downgrading IRWD lately?+
As of Nov 19, 2026, 1 of 2 active firms rate IRWD a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IRWD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.